Clinical-stage oncology company developing targeted cancer therapies, including antibody-drug conjugates, radioligand therapies, and a gamma secretase inhibitor
Clinical-stage oncology company developing targeted cancer therapies, including antibody-drug conjugates, radioligand therapies, and a gamma secretase inhibitor. Its pipeline includes clinical and preclinical candidates for desmoid tumors and multiple solid tumors.